Business Context and Reporting Period
Revelation Biosciences, Inc. (REVB) filed a Form 8-K on August 8, 2023, reporting a notice of noncompliance with Nasdaq listing standards. The company is incorporated in Delaware and operates as an emerging growth company.
Key Financial Metrics
This filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock price.
Material Changes
The material event is the receipt of a letter from Nasdaq notifying the Company of its failure to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, violating Listing Rule 5550(a)(2).
Guidance, Outlook, and Risks
- Grace Period: The Company has been granted an initial 180-calendar-day grace period to regain compliance, ending on February 5, 2024.
- Compliance Requirement: To regain compliance, the common stock must close at or above $1.00 per share for at least 10 consecutive business days within the grace period.
- Extension Possibility: If compliance is not met by the initial deadline, the Company may be eligible for an additional 180-day extension, contingent on meeting other listing standards (e.g., market value of publicly held shares) and potentially effecting a reverse stock split.
- Delisting Risk: If the Company fails to cure the deficiency or is ineligible for an extension, Nasdaq will provide notice that the stock is subject to delisting.
- Current Status: The stock remains listed and traded on The Nasdaq Capital Market pending the outcome of the grace period.
Investor Verification Checklist
- Monitor the daily closing bid price of REVB to track progress toward the $1.00 threshold.
- Verify if the Company announces a reverse stock split to address the bid price deficiency.
- Check for subsequent filings regarding the Company's market value of publicly held shares if an extension is sought.
- Review the Company's cash position in other filings to assess its ability to fund operations while addressing the listing issue.